H.U.Group Holdings, Inc.
3,736.00
JPY
+18.00
(+0.48%)
ISIN
JP3822000000
Return %
Stock
S&P 500
1Y
-5.75
14.20
3Y
52.83
81.12
5Y
32.15
68.34
Capital Structure
JPY
•
in mil. unless spec.Working Capital
JPY
•
in mil. unless spec.Growth Rates
JPY
•
in mil. unless spec.Quarterly Revenue
JPY
•
in mil. unless spec.Quarterly Earnings Per Share
JPY
•
in mil. unless spec.Quarterly Dividends Per Share
JPY
•
in mil. unless spec.Company Description
- CEO
- Goki Ishikawa
- Full Time Employees
- 5,157
- Sector
- Health services
- Industry
- Medical/Nursing services
- Address
- Akasaka Intercity AIR Tokyo TY Japan 107-0052
- IPO Date
- Sep 1, 1983
- Website
- hugp.com
- Similar Companies
- Business
- H.U. Group Holdings, Inc. serves as a pure holding company overseeing healthcare operations primarily through its three core segments: Lab Testing and its Related Services (LTS), In-Vitro Diagnostics (IVD), and Healthcare-related Services (HS), with a focus on clinical testing, diagnostic reagents, and support services for medical institutions. Founded on December 18, 1950, and headquartered at Akasaka Intercity AIR in Minato-ku, Tokyo, Japan, the company operates globally across Japan, the United States, Europe (including subsidiaries in Belgium, Sweden, and others), Hong Kong, China, and internationally, employing approximately 5,444 consolidated staff as of March 31, 2025. In the LTS segment, led by SRL, Inc., it holds Japan's leading 23.5% market share in commissioned clinical testing, processing over 200,000 daily tests including general screening, esoteric testing for disease causes and progression such as cancer and genetic analysis (with over 70% share in chromosome testing), and advanced services like whole genome sequencing, proteomics via Olink, and genomic medicine support for oncology and rare diseases; subsidiaries include Nihon Rinsho, Inc., Tokyo Central Pathology Laboratory, Inc., and Baylor Genetics (US). The IVD segment, anchored by Fujirebio Holdings, Inc. and FUJIREBIO INC., develops, manufactures, and sells immunoassay reagents and systems worldwide to over 100 countries, featuring the Lumipulse fully automated chemiluminescence enzyme immunoassay system with reagents for infectious diseases, neurodegenerative conditions like Alzheimer's (including sTREM2 assay launched in 2025 for research use only), cancer, and lifestyle diseases; it also pursues a contract development and manufacturing organization (CDMO) model supplying raw materials globally, alongside rapid diagnostics kits like ESPRINE for influenza and COVID-19, with subsidiaries such as Fujirebio Diagnostics, Inc. (US), Fujirebio Europe N.V. (Belgium), and ADx NeuroSciences N.V. The HS segment provides sterilization services via Nihon Stery, Inc., in-hospital support including central supply room operations, endoscopy assistance, medical equipment maintenance, and logistics; it also offers home-visit nursing, nursing care equipment rental and sales through Care’x Inc. and StarQ care Inc., targeting hospital outsourcing and at-home end-of-life care. Recent strategic developments include full-scale operations of the H.U. Bioness Complex, one of the world's largest lab facilities in Akiruno City, Tokyo, launched in 2021 to enhance LTS efficiency and automation; a 2022 group integration strategy termed the "second founding" unifying domestic sales under H.U. Frontier, Inc. and consolidating R&D at H.U. Group Research Institute G.K.; ongoing Medium-term Plan H.U. 2025 emphasizing CDMO growth in IVD, profitability reforms in LTS via process optimization, and HS foundation strengthening; relocation of headquarters to Akasaka Intercity AIR in 2023; establishment of H.U.POCkeT, Inc. as a B2C in-house venture; and Fujirebio's June 2025 launch of the Lumipulse G sTREM2 assay expanding neuro testing. Through subsidiaries like H.U. America, Inc. and SRL (Hong Kong) Limited, it targets medical institutions, hospitals, and global diagnostic firms, driving synergies in personalized medicine, early diagnostics, and healthcare innovation.